Atripla
From Proteopedia
(Difference between revisions)
(New page: A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on Jul...) |
|||
| Line 1: | Line 1: | ||
| - | A fixed-dose triple combination of emtricitabine, tenofovir and [[efavirenz]] (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla. | + | A fixed-dose triple combination of [[emtricitabine]], [[tenofovir]] and [[efavirenz]] (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla. |
Current revision
A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla.
